China: Draft policy that could impact the EDL, paediatrics and rare diseases

On 9 May 2022, the National Medical Products Administration (NMPA) announced a one-month public consultation on its draft regulation. The Regulations on the Implementation of the Drug Administration Law of the People's Republic of China could impact a series of areas including the Essential Drug List (EDL), paediatric medicines and rare diseases. Xin Zhao maps out the impact these potential new regulations could have.

↓

↓

‍